Gosia Riley

Sr. Director, Clinical Operations at Nuvalent

Gosia Riley is an Associate Director of Clinical Operations at Nuvalent. Gosia has over ten years of experience in clinical research and has worked on a variety of projects in the pharmaceutical and biotechnology industries.

Riley began their career as a Clinical Project Coordinator at Quintiles (now Outcome Sciences) in 2007. Gosia quickly rose through the ranks, becoming an Associate Clinical Project Manager and then a Clinical Project Manager. In this role, they were responsible for all aspects of project administration and data coordination for multiple large-scale registry studies.

In 2013, Riley left Quintiles to join Infinity Pharmaceuticals as a Senior Clinical Trial Associate. In this role, they provided support to the Associate Director and Project Manager, managed components of clinical trials, and coordinated and led project activities through close cooperation with a cross-functional study execution team.

In 2015, Riley joined Jounce Therapeutics as an Associate Director of Clinical Operations. In this role, they were responsible for leading a team of clinical operations professionals and overseeing all aspects of clinical trials from start to finish.

Riley has been with Nuvalent since 2016, where they currently serve as the Associate Director of Clinical Operations. In this role, they are responsible for overseeing all aspects of Nuvalent’s clinical trials, from study start-up to close-out.

Gosia Riley has a Bachelor's degree in Transatlantic Studies from Uniwersytet Jagielloński w Krakowie and a Master's degree in Political Science from the University of Massachusetts.

Location

Cambridge, United States

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices


Nuvalent

1 followers

Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses.


Employees

11-50

Links